For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...

European stocks advanced on Monday as risk appetite returned following five days of losses on the back of rising geopolitical risks in the Middle East, with gains in Milan and Madrid providing a boost ...

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys ...

Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its ...